[Effect of Zymosan on the properdin level of tumor patients]. 1961

S NAGY, and F HARTAI

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011134 Polysaccharides Long chain polymeric CARBOHYDRATES composed of MONOSACCHARIDES linked by glycosidic bonds. Glycan,Glycans,Polysaccharide
D011414 Properdin A 53-kDa protein that is a positive regulator of the alternate pathway of complement activation (COMPLEMENT ACTIVATION PATHWAY, ALTERNATIVE). It stabilizes the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb) and protects it from rapid inactivation, thus facilitating the cascade of COMPLEMENT ACTIVATION and the formation of MEMBRANE ATTACK COMPLEX. Individuals with mutation in the PFC gene exhibit properdin deficiency and have a high susceptibility to infections. Complement Factor P,Factor P, Complement
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015054 Zymosan Zymosan A

Related Publications

S NAGY, and F HARTAI
July 1972, Polski tygodnik lekarski (Warsaw, Poland : 1960),
S NAGY, and F HARTAI
April 1964, Biulleten' eksperimental'noi biologii i meditsiny,
S NAGY, and F HARTAI
January 1956, The Journal of experimental medicine,
S NAGY, and F HARTAI
March 1966, Die Naturwissenschaften,
S NAGY, and F HARTAI
January 1959, Zeitschrift fur Immunitatsforschung und experimentelle Therapie,
S NAGY, and F HARTAI
January 1963, Arerugi = [Allergy],
Copied contents to your clipboard!